Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel

International Urology and Nephrology

Volumn 46, Issue 8, 2014, Pages 1531-1535

  Sümbül, Ahmet Taner ^a   Sezer, Ahmet ^b   Abali, Hüseyin ^b   Köse, Fatih ^b   Gültepe, Ilhami ^c   Mertsoylu, Hüseyin ^b   Muallaoǧlu, Sadik ^b   Özyilkan, Özgür ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

Castration resistant prostate cancer; Neutrophil to lymphocyte ratio

Indexed keywords

DOCETAXEL; GONADORELIN; HEMOGLOBIN; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; PREDNISONE; TAXOID;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MALE; MEDICAL RECORD REVIEW; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATECTOMY; RETROSPECTIVE STUDY; BLOOD; CYTOLOGY; DISEASE FREE SURVIVAL; LYMPHOCYTE; MIDDLE AGED; NEUTROPHIL; PREDICTIVE VALUE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84906938403     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-014-0664-7     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512 (Pubitemid 39315317)
3. Yamashita H, Katai H (2010) Systemic inflammatory response in gastric cancer. World J Surg 34:2399-2400
4. Lukaszewicz-Zaja̧c M, Mroczko B, Gryko M, Kȩdra B, Szmitkowski M (2011) Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med 11:89-96
5. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N et al (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16:5805-5813
6. Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ et al (2011) Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer 11:489
7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
8. Lee DY, Hong SW, Chang YG, Lee WY, Lee B (2013) Clinical significance of preoperative inflammatory parameters in gastric cancer patients. J Gastric Cancer 13(2):111-116
9. Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A (2012) Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncol 17:1508-1514
10. Kishi Y, Kopetz S, Chun YS et al (2009) Blood neutrophil to lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16:614-622
11. An X, Ding PR, Li YH et al (2010) Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15:516-522
12. Cho H, Hur HW, Kim SW et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunother 58:15-23
13. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181-184 (Pubitemid 41254421)
14. Gondo T, Nakashima J, Ohno Y et al (2012) Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79:1085-1091
15. Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, Drake C, O'Dea P, Bermingham N, Keohane C, Grossman SA, Moylan EJ, O'Reilly S (2013) The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 114:149-154
16. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
17. Danila DC, Fleisher M, Scher HI (2011) Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17(12):3903-3912
18. Morris MJ, Autio KA, Basch EM, Danila DC, Larson S, Scher HI (2013) Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Semin Oncol 40(3):375-392
19. Jeong JH, Lim SM, Yun JY, Rhee GW, Lim JY, Cho JY et al (2012) Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology 83:292-299
20. Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436-444
21. Jarnicki A, Putoczki T, Ernst M (2010) Stat3: linking inflammation to epithelial cancer more than a "gut" felling? Cell Div 5:14
22. Yamanaka T, Matsumoto S, Teramukai S et al (2007) The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 73:215-220 (Pubitemid 351630053)
23. Keizman D, Ish-Shalom M, Huang P et al (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48:202-208